Synthesis and biological evaluation of 3,7-diazabicyclo[4.3.0]nonan-8-ones as potential nootropic and analgesic drugs.

A series of cis and trans 3,7-diazabicyclo[4.3.0]nonan-8-ones has been synthesized and tested for their ability to revert scopolamine-induced amnesia in the mouse passive-avoidance test. The racemates of the most potent compounds 4 and 7 were separated and tested, but no enantioselectivity was found for the nootropic activity. Compounds 4 and 7 and their enantiomers displayed interesting antihyperalgesic activity in two models of neuropathic pain (streptozotocin-induced and oxalilplatin-induced neuropathy) in comparison with pregabalin.

[1]  M. Prostran,et al.  Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice. , 2010, European journal of pharmacology.

[2]  I. Obrosova.  Diabetic painful and insensate neuropathy: Pathogenesis and potential treatments , 2009, Neurotherapeutics.

[3]  C. Albright,et al.  Therapeutic Strategies for Alzheimer’s Disease , 2008, Molecular Neurobiology.

[4]  S. Canpolat,et al.  Antinociceptive efficacy of levetiracetam in a mice model for painful diabetic neuropathy , 2008, Acta anaesthesiologica Scandinavica.

[5]  J. Levine,et al.  Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. , 2008, The journal of pain : official journal of the American Pain Society.

[6]  T. Wilens,et al.  Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. , 2007, Biochemical pharmacology.

[7]  P. Panegyres,et al.  Cognitive impairment in multiple sclerosis: Evidence-based analysis and recommendations , 2007, Journal of Clinical Neuroscience.

[8]  J. Kennedy.  Neuropathic pain: molecular complexity underlies continuing unmet medical need. , 2007, Journal of medicinal chemistry.

[9]  P. Bottoni,et al.  An update on pharmacological approaches to neurodegenerative diseases , 2007, Expert opinion on investigational drugs.

[10]  Philip D. Harvey,et al.  Treatment of cognitive deficits in schizophrenia. , 2006, Current opinion in investigational drugs.

[11]  N. Callizot,et al.  Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. , 2006, European journal of pharmacology.

[12]  C. Ghelardini,et al.  Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers. , 2006, CNS drug reviews.

[13]  C. Ghelardini,et al.  Enantioselective synthesis and preliminary pharmacological evaluation of the enantiomers of unifiram (DM232), a potent cognition-enhancing agent. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).

[14]  Y. Tanabe,et al.  Ti‐Crossed‐Claisen Condensation Between Carboxylic Esters and Acid Chlorides or Acids: A Highly Selective and General Method for the Preparation of Various β‐Keto Esters. , 2005 .

[15]  R. J. Cersosimo.  Oxaliplatin-Associated Neuropathy: A Review , 2005, The Annals of pharmacotherapy.

[16]  D. Alkon,et al.  Emerging targets for the pharmacology of learning and memory. , 2004, Pharmacological research.

[17]  C. Ghelardini,et al.  Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs. , 2004, Bioorganic & medicinal chemistry.

[18]  A. Pittaluga,et al.  AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram) , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[19]  C. Ghelardini,et al.  4-Aminopiperidine derivatives as a new class of potent cognition enhancing drugs. , 2003, Bioorganic & medicinal chemistry letters.

[20]  P. Sirois,et al.  Kinin B1 receptor antagonists inhibit diabetes-induced hyperalgesia in mice , 2003, Neuropeptides.

[21]  H. Ueda,et al.  Nonopioid and Neuropathy-Specific Analgesic Action of the Nootropic Drug Nefiracetam in Mice , 2002, Journal of Pharmacology and Experimental Therapeutics.

[22]  M. Jarvik,et al.  An Improved One-Trial Passive Avoidance Learning Situation , 1967, Psychological reports.

[23]  T. Yano,et al.  Mexiletine reverses oxaliplatin-induced neuropathic pain in rats. , 2010, Journal of pharmacological sciences.

[24]  Maria Novella Romanelli,et al.  Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. , 2002, Current pharmaceutical design.

[25]  Davidr . Evans,et al.  Contrasteric carboximide hydrolysis with lithium hydroperoxide , 1987 .

[26]  A. Malykh,et al.  Piracetam and Piracetam-Like Drugs From Basic Science to Novel Clinical Applications to CNS Disorders , 2022 .